psalexa
logo

Osteonecrosis Therapeutics Pipeline Analysis

Osteonecrosis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11257
Available Format:

Osteonecrosis is a condition in which degradation of bones occurs due to decrease of blood flow to bones in joints. Osteonecrosis is also known as avascular necrosis, aseptic necrosis, or ischemic necrosis. There are some risk factors associated with osteonecrosis such as alcohol use, injury to joints, increased pressure inside the bone, and steroidal medications. Some procedures such as chemotherapy, radiation therapy, and organ transplant are also found as the cause of osteonecrosis. The most common symptom associated with osteonecrosis is the occurrence of pain when putting weight on affected joints. Osteonecrosis can be diagnosed by bone biopsy, bone scan, computed tomography, magnetic resonance imaging and measuring the pressure inside the bone. University of California, Davis is in the process of developing LLP2A ALENDRONATE for the treatment of osteonecrosis. Bone Therapeutics SA is in the process of developing PREOB as a cell therapy for the treatment of osteonecrosis. Some of the companies/universities having the pipeline of osteonecrosis include Istituto Ortopedico Rizzoli, Bone Therapeutics S.A, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry